Key Highlights
- Wave Life Sciences shares declined 30% Thursday following the release of interim Phase 1 results from the INLIGHT obesity trial
- WVE-007 at a 240mg single dose achieved a placebo-adjusted 14% decrease in visceral fat across six months
- Study participants presented an average BMI of 32, substantially lower than conventional obesity trial populations
- Jefferies sustained its Buy rating with a $28 price target before the data announcement
- The company intends to initiate Phase 2a of INLIGHT during Q2 2026, focusing on higher-BMI individuals with additional health conditions
Wave Life Sciences unveiled interim Phase 1 results from its INLIGHT trial on Thursday, triggering a sharp market reaction. Shares plummeted 30% during the session, even as the company characterized the findings as encouraging.
The results focused on WVE-007, an investigational obesity therapy. Participants receiving a single 240mg dose demonstrated a placebo-adjusted visceral fat reduction of 14% over a six-month period, with a mean BMI of 32 kg/m².
Additional findings included a 16.5% baseline-to-endpoint improvement in the visceral fat-to-muscle ratio. Lean muscle mass rose by 2.4%, waist measurements decreased by 3.3%, and overall body weight fell 0.9% when adjusted for placebo.
The drug demonstrated tolerability at doses reaching 600mg. No participants withdrew from treatment due to adverse effects, and no severe safety events were recorded. Serum Activin E reductions persisted for at least seven months, suggesting viability for infrequent dosing schedules administered once or twice annually.
The complication? Study participants averaged a BMI of 32 — considerably lower than the BMI of 37 commonly observed in later-stage obesity clinical trials. This divergence complicates direct comparisons with competing therapeutic candidates.
Wave drew comparisons between WVE-007’s visceral fat outcomes and those of weekly semaglutide from an independent Phase 2 trial. That semaglutide study included participants with elevated BMI levels, prompting scrutiny of the comparison’s validity.
Market participants appeared to weigh these study design considerations against the intensely competitive obesity pharmaceutical landscape, where Novo Nordisk and Eli Lilly currently dominate.
Advancing to Phase 2a
Wave intends to launch the Phase 2a segment of INLIGHT during the second quarter of 2026. This upcoming study will recruit participants with BMI ranging from 35 to 50 who present with comorbid conditions — a demographic more representative of standard obesity trial cohorts.
The organization anticipates that this higher-BMI population will demonstrate more pronounced improvements in body composition and weight reduction. Findings from this phase will guide Wave’s strategic direction across obesity, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and cardiovascular disease indications.
One day prior to the data release, Jefferies reaffirmed its Buy rating and $28 price target on WVE shares, highlighting the RNA editing technology and the INHBE program as significant value catalysts.
Analyst Roger Song emphasized potential competitive benefits of Wave’s platform: absence of off-target editing effects, superior safety characteristics, and sustained therapeutic impact enabling convenient repeat administration.
Additional Pipeline Developments
In a separate development, Wave reclaimed complete rights to WVE-006 from GSK. The company will display a poster presentation at the American Diabetes Association meeting and anticipates sharing 400mg multiple ascending dose data alongside 600mg single ascending dose updates in May.
Mizuho increased its price target on WVE from $22 to $27 earlier this year, preserving an Outperform rating following Wave’s assumption of full ownership of WVE-006.
Wave recently disclosed Q4 and full-year 2025 financial results, acknowledging financial strain stemming from the conclusion of a significant partnership agreement. Revenue figures surpassed analyst projections, while earnings per share fell short of consensus estimates.
According to InvestingPro data, the company maintains a balance sheet with cash holdings exceeding debt obligations.
Data from the RestorAATion-2 trial evaluating WVE-006 will be shared at the American Thoracic Society International Conference in 2026, encompassing results from the 400mg multidose and 600mg single-dose participant groups.
